Equities

Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.04
  • Today's Change0.001 / 2.56%
  • Shares traded146.37k
  • 1 Year change-72.68%
  • Beta--
Data delayed at least 20 minutes, as of May 10 2024 04:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company. The Company is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The Company has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The Company's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

  • Revenue in AUD (TTM)0.00
  • Net income in AUD-46.82m
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tissue Repair Ltd457.52k-3.28m13.11m----0.825--28.67-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Oncosil Medical Ltd355.30k-11.71m13.53m2.00--2.30--38.08-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
BTC Health Ltd16.03k-8.26m13.94m1.00--2.578.44869.45-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Medlab Clinical Ltd943.67k-6.78m15.07m14.00------15.97-2.97-2.970.41330.56040.13012.2510.35---88.67-55.07-127.20-69.7590.4552.86-681.73-335.431.67-217.550.00---28.90-29.8318.55---30.00--
Amplia Therapeutics Ltd1.87m-4.46m16.30m1.00--0.8119--8.72-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Argent BioPharma Ltd1.32m-17.02m17.43m----10.36--13.16-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Noxopharm Ltd3.90m-12.13m17.53m1.00k--2.67--4.49-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Radiopharm Theranostics Ltd0.00-46.82m17.62m----0.5981-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Auscann Group Holdings Ltd2.05m-9.44m17.91m27.00------8.74-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Acrux Ltd14.46m-709.00k18.32m43.00--3.24--1.27-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
LTR Pharma Ltd-100.00bn-100.00bn19.01m----5.99----------0.0451----------------------------0.00---100.00---41.65------
Syntara Ltd9.83m-14.26m19.10m107.00--2.12--1.94-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Rhythm Biosciences Ltd157.67k-8.63m19.89m----14.54--126.14-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Algorae Pharmaceuticals Ltd84.10k-2.25m20.25m----5.59--240.77-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Immuron Ltd3.58m-3.88m20.52m6.00--1.17--5.74-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Data as of May 10 2024. Currency figures normalised to Radiopharm Theranostics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.60%Per cent of shares held by top holders
HolderShares% Held
Cranport Pty Ltd.as of 27 Sep 20222.68m0.60%
Data from 10 Apr 2024 - 10 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.